Login

Financial Snapshot

Revenue
TTM
$17.00K
Gross Margin
TTM
-311.76%
Net Income
TTM
-$29.05M
Current Assets
2025 Q4
Current Liabilities
2025 Q4
Current Ratio
2025 Q4
178.25%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
$9.290M
Cash
2025 Q4
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$10.91M

Stock Price

Loading...
Market Cap: $1.7056 Million

About PRF Technologies Ltd

PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The company employs 6 full-time employees The company went IPO on 2020-09-01. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.

Industry: Pharmaceutical Preparations Peers: Scinai Immunotherapeutics Ltd PolyPid Ltd Redhill Biopharma Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support